Evidence map›Paper›PMID 24475071›Full record

ArticlePloS one2014

Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.

Reema Gupta, Vikash Kumar, Pramod Kumar Kushawaha, Chandradev Pati Tripathi, Sumit Joshi, Amogh Anant Sahasrabuddhe, Kalyan Mitra, Shyam Sundar, Mohammad Imran Siddiqi, Anuradha Dube

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Article
  3. Metabolic Pathways ofPharmaceutics · 2022
    Review
  4. Article
  5. Article
  6. Review
  7. A Chimera of Th1 Stimulatory Proteins ofBioMed research international · 2021
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Using proteomics as a powerful tool to develop a vaccine against Mediterranean visceral leishmaniasis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Reema GuptaDivisions of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Vikash KumarMolecular and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India.
Pramod Kumar KushawahaDivisions of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Chandradev Pati TripathiDivisions of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Sumit JoshiDivisions of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Amogh Anant SahasrabuddheMolecular and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India.
Kalyan MitraElectron Microscopy, CSIR-Central Drug Research Institute, Lucknow, India.
Shyam SundarDepartment of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Mohammad Imran SiddiqiMolecular and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India.
Anuradha DubeDivisions of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Central Drug Research Institute · INInstitute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Th1 immune responses play an important role in controlling Visceral Leishmaniasis (VL) hence, Leishmania proteins stimulating T-cell responses in host, are thought to be good vaccine targets. Search of such antigens eliciting cellular responses in Peripheral blood mononuclear cells (PBMCs) from cured/exposed/Leishmania patients and hamsters led to the identification of two enzymes of glycolytic pathway in the soluble lysate of a clinical isolate of Leishmania donovani--Enolase (LdEno) and aldolase (LdAld) as potential Th1 stimulatory proteins. The present study deals with the molecular and immunological characterizations of LdEno and LdAld. The successfully cloned and purified recombinant proteins displayed strong ability to proliferate lymphocytes of cured hamsters' along with significant nitric-oxide production and generation of Th1-type cytokines (IFN-γ and IL-12) from stimulated PBMCs of cured/endemic VL patients. Assessment of their prophylactic potentials revealed ∼ 90% decrease in parasitic burden in rLdEno vaccinated hamsters against Leishmania challenge, strongly supported by an increase in mRNA expression levels of iNOS, IFN-γ, TNF-α and IL-12 transcripts along with extreme down-regulation of TGF-β, IL-4 and IL-10. However, animals vaccinated with rLdAld showed comparatively lesser prophylactic efficacy (∼ 65%) with inferior immunological response. Further, with a possible implication in vaccine design against VL, identification of potential T-cell epitopes of both the proteins was done using computational approach. Additionally, in-silico 3-D modelling of the proteins was done in order to explore the possibility of exploiting them as potential drug targets. The comparative molecular and immunological characterizations strongly suggest rLdEno as potential vaccine candidate against VL and supports the notion of its being effective T-cell stimulatory protein.

Indexed as

Amino Acid SequenceAnimalsAntigens, ProtozoanCricetinaeCytokinesDisease Models, AnimalEpitopes, T-LymphocyteFructose-Bisphosphate AldolaseGlycolysisHypersensitivity, DelayedImmunoglobulin GLeishmania donovaniLeishmaniasis VaccinesLeishmaniasis, VisceralLeukocytes, MononuclearLymphocyte ActivationAntigens, ProtozoanCytokinesEpitopes, T-LymphocyteFructose-Bisphosphate AldolaseImmunoglobulin GLeishmaniasis VaccinesNitric OxidePhosphopyruvate Hydratase

Identifiers

PMID24475071
PMCPMC3901665
OpenAlexW2055708951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.